Date: 2017-06-04
Type of
information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago
Company: Radius Health (USA - MA)
Product: elacestrant (RAD1901)
Action
mechanism: elective estrogen receptor degrader (SERD)/selective estrogen receptor modulator (SERM). Elacestrant is a nonsteroidal combined selective estrogen receptor modulator (SERM) and selective estrogen receptor degrader (SERD). The compound was discovered by Eisai and is under development by Radius Health and Takeda for the treatment of menopausal vasomotor symptoms (hot flashes) and estrogen receptor (ER)-positive advanced breast cancer, as well as endometrial cancer and kidney cancer.
Disease: estrogen receptor positive (ER+) breast cancer
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On June 4, 2017, Radius Health announced data from a fully enrolled ongoing Phase 1 study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. These data were presented at the 2017 American Society of Clinical Oncology Meeting in Chicago, Illinois (Evaluation of Elacestrant (RAD1901), a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer" Abstract 1014).
- As of the cut-off date of April 28, 2017, 40 patients have been treated in the fully enrolled elacestrant Phase I dose escalation and expansion cohorts at the 400 mg dose. These patients are all heavily pretreated ER+, HER2-negative advanced breast cancer patients who have received a median of 3 prior lines of systemic therapy and have evaluable advanced or metastatic disease. Of the enrolled patients, 22 patients met the RECIST measurable disease criteria at baseline and there were five confirmed partial responses in this group. Elacestrant was well-tolerated with the most common adverse events being low grade nausea and dyspepsia.
Is
general: Yes
